At what enterprise value was NOVA BIOMEDICAL acquired in 2025?

During the acquisition of NOVA BIOMEDICAL by PATRICIA INDUSTRIES in 2025, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b USD. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of NOVA BIOMEDICAL when it was acquired by PATRICIA INDUSTRIES?

The estimated EV/EBITDA multiple for NOVA BIOMEDICAL is in the range of 15x - 25x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was NOVA BIOMEDICAL acquired by PATRICIA INDUSTRIES?

NOVA BIOMEDICAL was acquired by PATRICIA INDUSTRIES in 2025.

What was the revenue of NOVA BIOMEDICAL at the time of the deal?

The revenue of NOVA BIOMEDICAL at the time of the deal is estimated to be in the range of 250M - 500M USD. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of NOVA BIOMEDICAL during the acquisition?

NOVA BIOMEDICAL's EBITDA is estimated to be in the range of 100M - 200M USD. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the NOVA BIOMEDICAL acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the NOVA BIOMEDICAL deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.novabiomedical.com/advanced-instruments-acquisition-of-nova-biomedical-completed/

← DATABASE

Home Database Healthcare & PharmaNOVA BIOMEDICAL

07/2025

NOVA BIOMEDICAL acquired by PATRICIA INDUSTRIES

UNITED STATES Life Sciences / Medical Devices / Diagnostic Equipment EV 1b - 4b USD

Context

Advanced Instruments has finalized the acquisition of Nova Biomedical, a maneuver designed to fundamentally reshape the global biopharma analytics and clinical diagnostic landscape. The strategic rationale for this transaction centers on a "portfolio-convergence" play, merging the target's industry-leading point-of-care and bioprocess monitoring technology with the group’s established leadership in osmometry and specialized lab analytics. This fusion effectively creates a specialized powerhouse in the life sciences tools sector, providing the organization with an end-to-end suite of analytical hardware required for modern drug development and patient monitoring.

NOVA BIOMEDICAL, which reported an EBITDA margin of in 2024, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Nova Biomedical operates as a premier technology organization dedicated to the engineering and distribution of advanced analytical instrumentation for the biopharmaceutical and clinical diagnostic sectors. The entity’s business model is centered on a proprietary framework of high-precision monitoring systems, including point-of-care analysis for critical analytes and mission-critical bioprocess analytics. Its value proposition is anchored in technical operational depth, facilitating real-time diagnostic monitoring in hospital settings and enhancing the structural efficiency of drug development in research laboratories. Strategically, the firm focuses on the integration of specialized consumables with industrialized hardware to ensure superior data integrity and repeatability. By maintaining a specialized focus on cell culture analysis and metabolic monitoring, the organization ensures a vital role in the structural advancement of precision medicine. The entity prioritizes technical innovation and regulatory excellence to support the complex requirements of global pharmaceutical manufacturing and critical care environments.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (USD)

Year

Rev

EBITDA

EBIT

2024

2023

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
08/2025	TERUMO	ORGANOX	UNITED KINGDOM	Medical Devices
08/2025	LGT CAPITAL PARTNERS	NEMERA	FRANCE	Medical Consumables
07/2025	BC PARTNERS	BIOGARAN	FRANCE	Pharma & Biotech
05/2025	IK PARTNERS	BIOBANK	FRANCE	Implants & Prosthetics
05/2025	OTTOBOCK	MATTON ORTHOMEDI	BELGIUM	Implants & Prosthetics
04/2025	CINVEN	NUTRISENS	FRANCE	Nutrition & Dietary Supplements
04/2025	NORGINE	THERAVIA	FRANCE	Generics / Labs
04/2025	IK PARTNERS	STERIMED	FRANCE	Medical Consumables
04/2025	INSTITUT MERIEUX / ARCHIMED	CEVA SANTE ANIMALE	FRANCE	Animal Health
04/2025	PATIENT SQUARE CAPITAL	PATTERSON COMPANIES	UNITED STATES	Medical Consumables

REFERENCES

Valuation range: EV 1b - 4b USD

Revenue range: 250M - 500M USD

EBITDA range: 100M - 200M USD

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of NOVA BIOMEDICAL by PATRICIA INDUSTRIES are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: nova biomedical

Acquirer: patricia industries